Related Experiment Video
Updated: Aug 5, 2026
06:51
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
Non-Severe Clostridium difficile Infection
Kazi I Ullah1, Olga C Aroniadis2
1Department of Gastroenterology, Stony Brook University Hospital, Stony Brook, NY, USA.
Gastroenterology Clinics of North America
|July 31, 2026
Summary
This review details non-severe Clostridium difficile infection (CDI), covering its definition, diagnosis, prevention, and treatment. It also explores predictors of treatment failure and future research directions for managing this common infection.
Area of Science:
- Infectious Diseases
- Microbiology
- Gastroenterology
Background:
- Clostridium difficile infection (CDI) presents a spectrum of severity, from mild diarrhea to life-threatening conditions.
- Management strategies are tailored based on CDI severity classification: non-severe, severe, or fulminant.
- Non-severe CDI requires specific diagnostic and therapeutic considerations.
Purpose of the Study:
- To provide a comprehensive overview of non-severe Clostridium difficile infection (CDI).
- To review the definition, diagnostic methods, prevention, and treatment of non-severe CDI.
- To identify predictors of treatment failure and discuss future research in non-severe CDI management.
Main Methods:
- Literature review focusing on non-severe Clostridium difficile infection (CDI).
- Analysis of diagnostic criteria and clinical manifestations of non-severe CDI.
- Evaluation of current and emerging treatment strategies for non-severe CDI.
Main Results:
- Non-severe CDI is characterized by specific clinical parameters and absence of severe complications.
- Various treatment options exist for non-severe CDI, with varying efficacy.
- Predictors for treatment failure in non-severe CDI have been identified.
Conclusions:
- Effective management of non-severe CDI relies on accurate diagnosis and appropriate treatment selection.
- Understanding treatment failure predictors can optimize patient outcomes.
- Ongoing research is crucial for advancing the management of non-severe CDI.
Keywords:
Antimicrobial stewardshipClostridioides difficileFidaxomicinNon-severe CDIPreventionRecurrenceVancomycinMore Related Videos
Related Concept Videos
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:18Bacterial Gastroenteritis
Bacterial gastroenteritis, characterized by diarrhea, abdominal cramps, and vomiting, is often caused by ingestion of contaminated food or water and is frequently associated with pathogenic Escherichia coli strains. These microbes exploit two principal mechanisms to inflict disease.Shiga toxin–producing E. coli, also referred to as STEC—notably O157:H7—release Shiga toxins that target ribosomes, blocking protein synthesis. The B subunit of the toxin binds the host glycolipid receptor...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:17Chronic Bowel Disorders: Introduction
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:20Inflammatory Bowel Disease IV: Clinical Manifestations
Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...